What is it about?
Tenapanor (a small molecule that inhibits paracellular phosphate absorption) is being studied as a non-binder oral therapy for the treatment of patients on dialysis with hyperphosphatemia. Here we show it significantly reduced serum phosphorus concentration from baseline, compared with placebo, when used with phosphate binders as a dual-mechanism treatment.
Featured Image
Why is it important?
A significantly larger proportion of patients randomized to tenapanor plus binder achieved a serum phosphorus concentration <5.5 mg/dl at all time points compared with placebo plus binder. This suggests tenapanor could be a new tool to help manage hyperphosphatemia in patients on dialysis not reaching their goal on binders.
Perspectives
If approved, tenapanor may be a great new treatment option used alone or in combination with phosphate binders to help patients with hyperphosphatemia achieve and maintain goal serum phosphate values. It may also help decrease the pill burden of using phosphate binders alone.
Pablo Pergola
Renal Associates PA
Read the Original
This page is a summary of: A Randomized Trial of Tenapanor and Phosphate Binders as a Dual-Mechanism Treatment for Hyperphosphatemia in Patients on Maintenance Dialysis (AMPLIFY), Journal of the American Society of Nephrology, March 2021, American Society of Nephrology,
DOI: 10.1681/asn.2020101398.
You can read the full text:
Contributors
The following have contributed to this page
